Genome & Company (CEO Bae Ji-soo and Park Han-soo), a leading global immunotherapy company, will participate in Europe’s largest bio partnering event ‘BIO-EU 2021’, which will be held online for 4 days from October 25th to 28th (local time).
BIO-EU 2021, which will be held online this year like last year, is the largest annual event in the biopharmaceutical industry with a large number of multinational pharmaceutical companies from over 50 countries around the world participating every year since 1995. This is a place where discussions regarding business opportunities such as licensing and joint development of new drug candidates are rapidly progressing.
At this event, Genome & Company will hold partnering meetings with a number of global pharmaceutical companies. We plan to introduce the progress of pipeline research and development, including new target immunotherapy candidate ‘GENA-104’ and brain disease microbiome treatment ‘SB-121’, and actively promote partnering activities. In particular, in the case of ‘GENA-104’, as it is the first business deal in the company’s new antibody drug pipeline, the strategy is to focus on the optimal partner and optimal conditions.
‘GENA-104’, a new target immuno-anticancer drug, is a candidate for a new antibody drug that inhibits ‘CNTN-4’, a new immuno-anticancer target discovered by Genome & Company. Starting with the signing of a contract development (CDMO) contract with Samsung BioLogics in December last year, the research results of the new target ‘CNTN-4’ and the immunotherapy drug ‘GENA-104’ targeting it were disclosed at the AACR in April this year.
‘SB-121’, the main pipeline of Scioto Bioscience, a subsidiary of Genome & Company, is a brain disease microbiome treatment with main indications for Autism Spectrum Disorder (ASD) and Neonatal Necrotizing Enterocolitis (NEC). . ‘SB-121’ is a Lactobacillus.reuteri ( L.reuteri ) strain found in a healthy mother’s breast milk. ABT Platform (Activated Bacterial Therapeutics™, a proprietary platform that maximizes the efficacy of Scioto Bioscience’s microbiome strain) ABT platform) technology is applied to increase the stability and efficacy of the strain in the body. Scioto Bioscience is currently in Phase 1 clinical trials after receiving Phase 1 IND approval from the U.S. FDA in May.
Bae Ji-soo, CEO of Genome & Company, said, “At the last BIO EU, we confirmed high interest in our pipeline from a number of global pharmaceutical companies at home and abroad,” and added, “We are proud of the performance of our pipeline business deals for new antibody drugs and microbiome immunotherapy anticancer drugs.” “With that goal in mind, we will actively seek out global partnering opportunities,” he said.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ news